FGEN: Rasio rega marang dodolan FibroGen Inc
A liquidity crisis and the threat of bankruptcy due to failed trials place FibroGen, Inc. (FGEN) in a precarious position. The price/sales multiple illustrates this instability, where 4.70 captures the current state of the parameter. The firm's survival relies on royalties from Asia amid collapsed pricing power, while its primary earnings are based on roxadustat sales through strategic partners.
%20Multiplikator%20P%2FS&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_FGEN_-_FibroGen-Inc._-_PS-Multiple "FGEN - Koefisien rega marang pendapatan FibroGen Corporation ing rentang 04.07.2022 - 08.01.2026 | 👁️GURU.Markets👁️")
Rincian metrik lan analitis perusahaan FibroGen Corp (FGEN)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- indikator nilai aset resik miturut neraca:
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi FibroGen, Inc.|FGEN - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal FibroGen Corporation|FGEN - Gunggung utang perusahaan|Utang marang aset resik FibroGen Corp|FGEN - Utang jangka dawa perusahaan|Utang jangka cendhak FibroGen|Rasio likuiditas darurat fibrogen.com
- data bathi resik lan rasio valuasi:
FGEN - Penghasilan resik|Penghasilan resik sing dikarepake FibroGen, Inc.|FGEN - Pangali P/E|Kapitalisasi marang proyeksi bathi FibroGen Inc|FGEN - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan FibroGen Corp|FGEN - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan FibroGen|FGEN - Bathi resik saben saham sajrone 12 wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan fibrogen.com|FGEN - Wutah bathi ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep FibroGen, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:FibroGen, Inc.
The P/S metric is critical for stress-testing assets and identifying overvalued companies, as it compares market capitalization to annual sales volume to demonstrate how much investors are willing to pay per unit of revenue. The current price/sales multiple for FibroGen, Inc. (FGEN) is 4.70. This chart confirms the resilience of FibroGen, Inc., whose biotechnological developments are shielded from macroeconomic shocks due to stable demand for innovative medicine.
Perusahaan pesaing
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Rasio rega marang dodolan|Jyong Biotech Corp - Multiplikator P/S|Koefisien rega marang pendapatan Ligand Corp LGND|AMRX: Multiplikator P/S|PRGO (perrigo.com) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Alvotech SA|LQDA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP - Rega marang dodolan|Multiplikator P/S MNKD (MannKind Corporation)|Multiplikator rega marang pendapatan amphastar.com|Pacira BioSciences, Inc. - Multiplikator P/S|Rega marang dodolan ARS Pharmaceuticals Inc|Theravance (TBPH) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan AQST|Kapitalisasi marang pendapatan SCPH|TECX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S TNXP|Koefisien rega marang pendapatan sxtchina.com|Rasio rega marang pendapatan Eupraxia Pharmaceuticals Inc. EPRX|BHST: Rasio kapitalisasi marang pendapatan|eXoZymes Inc - Multiplikator P/S|Oramed Pharmaceuticals (ORMP) - Kapitalisasi marang pendapatan|ENTX (enterabio.com) - Kapitalisasi marang pendapatan|HYFT - Koefisien rega marang pendapatan|ABVC (ABVC BioPharma Inc) - Multiplikator P/S|Cumberland Corp - Rasio rega marang dodolan|Multiplikator P/S QNTM|telomirpharma.com (TELO) - Multiplikator rega marang pendapatan|Multiplikator P/S RANI (Rani Therapeutics Holdings, Inc.)|Synergy CHC Corp. (SNYR) - Rega marang dodolan|RLYB - Rasio rega marang pendapatan|LEXX (Lexaria Bioscience) - Rasio kapitalisasi marang pendapatan|Pulmatrix, Inc. (PULM) - Rasio rega marang pendapatan|Rasio rega marang dodolan PTHL (Pheton Holdings)|APM (Aptorum Group Ltd) - Multiplikator P/S|LYRA: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S IBO|Multiplikator P/S tnfpharma.com (TNFA)|Rasio rega marang pendapatan cbdMD YCBD|Rasio kapitalisasi pasar marang pendapatan PRFX|CYTO - Rasio rega marang pendapatan|Lipella Pharmaceuticals Inc (LIPO) - Kapitalisasi marang pendapatan|OPTN: Multiplikator P/S|Pieris Pharma (PIRS) - Multiplikator P/S|Kapitalisasi marang pendapatan PROC|PTPI: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Qilian International Holding (QLI)|SLRN - Rega marang dodolan|TFF Pharma - Kapitalisasi marang pendapatan
